Your browser doesn't support javascript.
loading
Effect of different doses of gadolinium contrast agent on clinical outcomes in MS.
Ackermans, Nathalie; Taylor, Carolyn; Tam, Roger; Carruthers, Robert; Kolind, Shannon; Kang, Heejun; Freedman, Mark S; Li, David Kb; Traboulsee, Anthony L.
Afiliación
  • Ackermans N; University of British Columbia, Department of Medicine (Neurology), Canada.
  • Taylor C; University of British Columbia, Department of Statistics, Canada.
  • Tam R; University of British Columbia, Department of Radiology, Canada.
  • Carruthers R; University of British Columbia, Department of Medicine (Neurology), Canada.
  • Kolind S; University of British Columbia, Department of Medicine (Neurology), Canada.
  • Kang H; University of British Columbia, Department of Radiology, Canada.
  • Freedman MS; University of Ottawa and the Ottawa Hospital Research Institute, Canada.
  • Li DK; University of British Columbia, Department of Medicine (Neurology), Canada.
  • Traboulsee AL; University of British Columbia, Department of Radiology, Canada.
Mult Scler J Exp Transl Clin ; 5(1): 2055217318823796, 2019.
Article en En | MEDLINE | ID: mdl-30800415
OBJECTIVE: The objective of this paper is to evaluate potential dose-dependent adverse effects of gadolinium-based contrast agents (GBCAs) on MS progression. METHODS: Outcomes from a cohort of 612 secondary progressive MS (SPMS) patients, enrolled in a two-year, placebo-controlled (negative) trial assessing the efficacy of MBP8298, were acquired. Patients received one to four (infrequent cohort; IFR) or 5-11 (frequent cohort; FR) GBCA injections between week 4 and week 104. The primary outcome was the change in Expanded Disability Status Scale (EDSS) and time to confirmed EDSS progression. Secondary outcomes included the changes in the Multiple Sclerosis Functional Composite (MSFC), Timed 25-Foot Walk (T25FW), 9-Hole-Peg Test (9HPT), and Paced Auditory Serial Addition Test (PASAT) from baseline to week 104. RESULTS: The 512 IFR and 100 FR participants showed no differences in baseline demographics or disease history. The mean change from baseline to week 104 in EDSS was +0.21 (IFR) and +0.13 (FR); MSFC -0.38 (IFR) and -0.14 (FR); T25FW +1.28 (IFR) and +0.55 (FR); 9HPT -0.06 (IFR) and -0.08 (FR); and PASAT +0.22 (IFR) and +0.20 (FR). The FR to IFR progression hazard ratio equaled 0.68 (p = 0.09). There were no significant differences in any of the outcomes between the two cohorts. CONCLUSION: There were no differences in the disability progression measures between the two cohorts, indicating that gadolinium does not result in greater clinical worsening in SPMS after a two-year period.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2019 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2019 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos